Figure 2.
Biomarker concentrations in the nasal polyp tissue biopsies of patients with CRSwNP in the biopsy subgroup. Concentrations at baseline and Week 16 (end of treatment) in the dupilumab (n = 8) and placebo (n = 4) groups. (A) Total IgE, (B) ECP, (C) eotaxin‐2, (D) eotaxin‐3, (E) PARC, and (F) IL‐13. ECP, eosinophil cationic protein; IgE, immunoglobulin E; IL, interleukin; PARC, pulmonary and activation‐regulated chemokine. P values for end of treatment vs baseline are reported